Celldex Therapeutics, Inc. · NASDAQ:CLDX
Celldex Therapeutics — Merger or Acquisition (June 2009)
17 slides from Celldex Therapeutics's merger presentation, Jun 9, 2009
Slide 1: Corporate Presentation June 2009
Corporate Presentation June 2009
Slide 2: Forward Looking Statement
Forward Looking Statement This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forwa
Slide 3: Celldex Highlights
Celldex Highlights Diversified immunotherapy company with maturing and growing pipeline CDX-110 Phase 2 in GBM CDX-1307 Phase 1 in epithelial tumors Additional candidates entering trials in 2009 and 2010 Precision Targeted Immunotherapy Platform (PTIP) Pipeline generator to create novel disease-spec
Slide 4: The Precision Targeted Immunotherapy Engine: Fueling New Treatments for Serious Diseases
The Precision Targeted Immunotherapy Engine: Fueling New Treatments for Serious Diseases
Slide 5: Benefits of Proposed Acquisition of CuraGen
Benefits of Proposed Acquisition of CuraGen Supports the PTI Platform with 11 oncology-focused human antibodies vetted and selected from target/antibody deal with Abgenix; fully-owned Phase 2 candidate CR011 (breast cancer and melanoma) Antibody-drug conjugate targeting GPNMB IND-track CR014 (renal
Slide 6: Transaction Details
Transaction Details All-stock transaction valued at $94.5 million CRGN to deliver a minimum of $68.6 million in cash CLDX to assume $14.1 million in CRGN debt Minimum yield of $54.5 million net cash; increases Company cash to at least $96 million and runway into 2012 Net of acquisition related costs
Slide 7: Celldex/CuraGen Pro Forma Pipeline
Celldex/CuraGen Pro Forma Pipeline CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 CDX-110 CR011 CR011 CDX-1307 CDX-1401 CDX-1135 Glioblastoma multiforme Breast cancer Melanoma Epithelial cancers Multiple solid tumors Renal disease Partnered with Pfizer CuraGen Program CuraGen Program Pilot
Slide 8: CDX-110 – EGFRvIII Vaccine in GBM
CDX-110 – EGFRvIII Vaccine in GBM Active immunotherapy/cancer vaccine comprised of the EGFRvIII peptide linked to KLH EGFRvIII is a variant of EGFR Highly tumor specific Known as a true oncogene Continually promotes tumor growth Originally discovered in GBM, also expressed in other cancers such as b
Slide 9: ACT II Time to Progression
ACT II Time to Progression = 15.2 Months = 6.3 Months = 14.2 Months Source: John Sampson, ASCO, 2009 p=0.0237 p=0.041 Time to Progression 0 10 20 30 40 50 60 0 10 20 30 40 50 60 70 80 90 100 ACT II ACTIVATE Controls Months
Slide 10: ACT II Overall Survival
Source: John Sampson, ASCO, 2009 *ACT II OS data is not yet final = 26.0 Months = 23.6 Months* = 15.0 Months ACT II ACTIVATE Controls p=0.001 p=0.0194 0 10 20 30 40 50 60 0 10 20 30 40 50 60 70 80 90 100 Months Percent survival ACT II Overall Survival
Slide 11: CR011 – Antibody Drug Conjugate
CR011 – Phase 2 Antibody Drug Conjugate (CRGN) Human mAb linked to MMAE (monomethyl-auristatin E), a potent cell-killing drug Targets GPNMB, predominantly and highly expressed in melanoma, breast cancer and glioma tumors Currently completing Phase 1/2 studies in melanoma and breast cancer Breast can
Slide 12: CDX-1307 – Phase 1/2 Antibody Vaccine
CDX-1307 – Phase 1/2 Antibody Vaccine Dendritic-cell-targeted immunotherapy designed to focus the immune system against hCG Beta Localizes in dermal DCs following id administration Both local and systemic administration can provide immunity despite advanced disease and high levels of circulating ant
Slide 13: CDX-1401 - Phase 1/2 mAb Fusion Protein
CDX-1401 - Phase 1/2 mAb Fusion Protein Monoclonal antibody specific to DEC-205 dendritic cell receptor Linked to the NY-ESO-1 tumor antigen NY-ESO-1 expressed on many solid tumors Phase 1/2 Studies to commence in 2009 Dose-escalation study with TLR agonist plus Phase 2 expansion
Slide 14: Additional Assets for PTI Platform
Additional Assets for PTI Platform Immune Modulators Flt3 ligand Acquired from Amgen in March 2009 Immune cell growth factor with demonstrated safety and biological activity in Phase 1/2 studies TLR agonists Hiltonol, Resiquimod Immune cell activators Therapeutic Antibody Programs Human Antibody por
Slide 15: Near Term Milestones
Near Term Milestones Close CuraGen transaction and integrate assets Continue to progress core clinical programs Phase 2 ACT III study of CDX-110 in GBM; design of randomized study in GBM Phase 2 CR011 studies in breast cancer and melanoma; determine next steps for CR011 development in breast cancer
Slide 16: Celldex Highlights
Celldex Highlights Diversified immunotherapy company with maturing and growing pipeline CDX-110 Phase 2 in GBM CDX-1307 Phase 1 in epithelial tumors Additional candidates entering trials in 2009 and 2010 Precision Targeted Immunotherapy Platform (PTIP) Pipeline generator to create novel disease-spec
Slide 17: www.celldextherapeutics.com
www.celldextherapeutics.com
Celldex Therapeutics — Merger or Acquisition (June 2009) on 6ix